biosimilars news from FierceBiotech
News
Live from BIO: For Biotechs, a bright future with challenges
At the first day of BIO 2008 conference I met with Murry Aitken, Senior VP of Healthcare Insight at IMS Health. IMS just released a report on the sales growth of biologic drugs in 2007. Global sales Read more...
Biotech's next big opportunity: Follow-ons?
Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...
Genzyme gets biosimilar rejection, builds R&D plant
The FDA have given a thumbs down to Genzyme's request for permission to sell its Pompe disease drug Read more...
In new approach, R&D units are spun off
In the old model for drug discovery, R&D is needed to provide a regular crop of new drug prospects to replace the therapies coming off patent. But that's not so in the generics world. Some of Read more...
Pfizer's future rests with biotech
At this week’s Bear Stearns Healthcare Conference, Pfizer discussed its plans for the future with analysts. As we all know, Pfizer is facing a major loss of sales when its best-selling drug Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets